S1803: PHASE III STUDY OF DARATUMUMAB/rHuPH20 (NSC- 810307) + LENALIDOMIDE OR LENALIDOMIDE AS POST-AUTOLOGOUS STEM CELL TRANSPLANT MAINTENANCE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA (MM) USING MINIMAL RESIDUAL DISEASE TO DIRECT THERAPY DURATION (DRAMMATIC STUDY)
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
Rocky Mountain Regional VA Medical Center
Study ID
Protocol Number: 19-1589
More information available at ClinicalTrials.gov: NCT04071457
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers